Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens

Korro Bio reported a widening net loss in 2025 to $117.3 million, up from $83.6 million in 2024, despite an increase in collaboration revenue and progress in its RNA-editing pipeline. The company nominated KRRO-121 as a development candidate for hyperammonemia and advanced its alpha-1 antitrypsin deficiency program. An $85 million private placement in March 2026 is expected to extend Korro Bio’s cash runway into the second half of 2028.